Urokinase an enzyme protein isolated from the urine of a healthy person or
obtained from human kidney tissue culture. Can be direct effects on endogenous
fibrinolysis system, can into fibrinolytic enzyme catalytic cracking
fibrinolytic enzyme, which can not only degradation of fibrin clot, also can
degrade fibrinogen in blood, and clotting factor Ⅴ and blood coagulation factor
Ⅷ etc, so as to play a role of thrombolysis. Urokinase has a quick and good
effect on newly formed thrombus, and can also improve the activity of vascular
ADP enzyme, inhibit adp-induced platelet aggregation, and prevent thrombosis.
After intravenous infusion, the fibrinolytic activity in the patient's body was
significantly increased, and the fibrinolytic activity returned to the original
level after several hours of drug withdrawal.
Urokinase can treat circulatory system diseases
(1) clinical study of low dose urokinase combined with defibrase in the
treatment of progressive cerebral infarction
Progressive stroke is one of the most difficult to treat in cerebral
infarction. At present, low-molecular-weight heparin is the first-line
anticoagulant drug at home and abroad. In domestic studies, low-molecular-weight
heparin calcium was used as the control in the treatment of progressive cerebral
infarction by low-dose urokinase combined with defibrase. The results showed
that the total effective rate of the treatment group was higher than that of the
control group, and there was no case of cerebral hemorrhage. It is concluded
that the combination of low-dose urokinase with defibrase can achieve stable
thrombolytic, defibrinolytic and anticoagulant effects, and the treatment effect
of progressive cerebral infarction is significant, which is worthy of clinical
promotion.
(2) high dose urokinase thrombolytic therapy for deep venous thrombosis of
lower extremities after implantation of inferior vena cava filter
Thrombolytic therapy with high dose urokinase for deep venous thrombosis of
lower extremity after implantation of inferior vena cava filter. Urokinase (UK)
dosage: 9 million U ~ 16 million U. Domestic research suggests 13 subjects,
including: healing in 2 cases, 9 cases were markedly effective, effective in 2
cases, ineffective 0 cases, does not appear in the process of thrombolysis
symptoms of pulmonary embolism and bleeding. Conclusion after inferior vena cava
filter placement by limb high-dose intravenous urokinase thrombolysis treatment
of lower extremity deep vein thrombosis is safe and effective.
(3) application of urokinase with different doses in blocking of deep
venous catheter in patients with malignant tumors
Objective: to investigate the clinical effect of urokinase with different
doses in dredging the blockage of deep venous catheter in malignant tumors.
Methods 2 million U urokinase was added to 500ml normal saline (concentration of
4000U/ml) for dredging catheter treatment, and the control group was treated
with urokinase with a concentration of 2000U/ml for dredging catheter treatment.
Results the total recanalization rate of the observation group was 95.56%,
significantly higher than the control group of 86.04%, the difference was
statistically significant (P0.05). Conclusion 4000U/ml urokinase can effectively
and safely dredge the blocked deep venous catheter in malignant tumors.
(4) efficacy analysis of low-dose urokinase combined with
low-molecular-weight heparin sodium in the treatment of elderly patients with
acute coronary syndrome
Studies have shown that low dose urokinase combined with low molecular
weight heparin sodium in the treatment of elderly patients with acute coronary
syndrome has a significant clinical effect, which is significantly better than
the conventional treatment (beta blockers, calcium antagonists, nitrate esters,
aspirin, clopidogrel, etc.).